Tirzepatide Contraindications: Safety & Who Should Avoid

Last reviewed: May 26, 2026

Last updated: May 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Tirzepatide is contraindicated in patients with a personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), active pancreatitis, pregnancy, and diabetic retinopathy requiring acute treatment. Understanding these absolute contraindications is essential before considering any tirzepatide formulation.

Beyond absolute contraindications, relative safety concerns—such as kidney function, gallbladder history, and gastrointestinal tolerance—require individualized provider assessment. PlexusDx supports precision-wellness conversations by layering genetic predisposition data with clinical contraindication screening.

Absolute Contraindications: Non-Negotiable Safety Barriers

Absolute contraindications are conditions where tirzepatide use is medically inadvisable regardless of benefit potential. Patients with prior medullary thyroid carcinoma or family history of MEN2 syndrome must avoid tirzepatide because of GLP-1 receptor activation on thyroid C-cells and theoretical malignancy risk.

Active or severe pancreatitis, pregnancy, and acute diabetic retinopathy complications also represent absolute contraindications. Regulatory labeling reflects these barriers based on clinical trial data and post-market safety monitoring across multiple GLP-1 agonists and dual agonists.

Relative Contraindications and Eligibility Assessment Framework

Relative contraindications involve medical conditions that increase tirzepatide risk but may not fully exclude use. Kidney function decline, personal pancreatitis history (resolved), gallbladder disease, and certain gastrointestinal conditions warrant careful provider review, dose adjustment, and monitoring before initiating treatment.

Clinical Factor	Safety Consideration	Typical Provider Action
eGFR <15 or dialysis-dependent	Limited safety data; tirzepatide accumulation risk	Usually contraindicated; specialist consultation required
History of pancreatitis (resolved)	Recurrence risk with GLP-1 use; monitor amylase/lipase	Relative—requires baseline screening and ongoing monitoring
Gallbladder disease or cholecystectomy	Tirzepatide may increase biliary-related events	Relative—baseline ultrasound and symptom counseling advised
Diabetic retinopathy requiring treatment	Rapid glucose lowering may worsen vision acutely	Contraindicated until retinopathy stabilized or treated
Pregnancy or planning pregnancy	No teratogenicity data; discontinue 3 months preconception	Absolute contraindication during pregnancy

Genetic Predispositions and Individual Tolerance Patterns

Genetic variants in GIPR and MC4R, and FTO pathways may influence tirzepatide tolerance and metabolic response, though they do not determine absolute eligibility. PlexusDx Precision Peptide Genetic Test examines predispositions in these peptide signaling genes to help providers understand individual variation in medication response.

Variants like GIPR rs1800437 may influence receptor sensitivity or gastrointestinal side effect risk, providing clinical context for dose escalation decisions and monitoring intensity. Genetic insight does not replace contraindication screening but can support personalized risk-benefit conversations.

Medication Interactions and Comorbidity Considerations

Tirzepatide may interact with insulin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and certain blood pressure medications, increasing hypoglycemia or dehydration risk. Patients on these agents require baseline adjustment conversations and close glucose or blood pressure monitoring post-initiation.

Comorbidities including heart failure, adrenal insufficiency, thyroid disease (non-cancer), and severe dehydration warrant provider discussion before starting. While not absolute contraindications, these conditions demand enhanced monitoring, dose timing, and possible medication adjustments to maintain safety.

Provider-Led Eligibility Screening and PlexusDx Support Framework

Comprehensive eligibility assessment requires baseline labs (renal function, liver function, amylase, lipase, TSH, calcitonin where indicated), personal and family medical history review, and current medication audit. PlexusDx partners with qualified providers to streamline this screening before compounded tirzepatide initiation.

PlexusDx Precision Peptide Genetic Test results should be interpreted alongside clinical contraindication screening, not as replacements for medical evaluation. Genetic predispositions may help providers tailor monitoring intensity, dose escalation timing, and side effect counseling, supporting more informed shared decision-making.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic testing may help provide context around individual peptide pathway predispositions that influence tirzepatide tolerance and response variability, but genetic variants do not override absolute contraindications or replace mandatory medical screening. Variants in GIPR, MC4R, and FTO pathways can support provider conversations about expected side effect profiles or dose escalation strategies.

The Precision Peptide Genetic Test reveals predispositions in peptide signaling genes that correlate with GLP-1 agonist and dual-agonist response patterns. These genetic insights should be interpreted with a qualified healthcare provider as one data point within a comprehensive safety and efficacy assessment, never as a predictor of exact medication response or a bypass for contraindication evaluation.

By combining PlexusDx genetic context with provider-led contraindication screening, patients and clinicians can have more personalized conversations about whether compounded tirzepatide aligns with individual health profiles, genetic predispositions, and treatment goals. This layered approach supports precision-wellness decision-making grounded in both clinical safety and individual biologic variation.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Which conditions does this article treat as absolute barriers to tirzepatide?

The post names a personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, active or severe pancreatitis, pregnancy, and diabetic retinopathy complications requiring acute treatment. It explains the thyroid exclusion by pointing to GLP-1 receptor activity on thyroid C-cells and a theoretical malignancy risk, and says regulatory labeling reflects these barriers based on trial data and post-market safety monitoring.

How does the post separate an absolute contraindication from a relative one?

An absolute contraindication, in the article's framing, is a condition where use is medically inadvisable no matter how large the potential benefit. A relative contraindication raises risk but may not fully exclude treatment; the post gives declining kidney function, resolved pancreatitis, gallbladder disease and certain gastrointestinal conditions as examples that call for provider review and monitoring instead of automatic exclusion.

What does the eligibility table say about severely reduced kidney function?

The row for an eGFR under 15 or dialysis dependence describes limited safety data and a risk of tirzepatide accumulation. The listed provider action is that it is usually contraindicated and that specialist consultation is required. The article separately notes that severe dehydration and interactions with other agents can compound kidney-related risk, which is why baseline renal labs appear in its screening list.

Why does the article say eye disease can delay starting treatment?

It states that rapid glucose lowering may acutely worsen vision in someone with diabetic retinopathy that requires treatment, so the table marks that situation as contraindicated until the retinopathy is stabilized or treated. This is framed as a timing issue rather than a permanent exclusion. The post also recommends ophthalmology input be part of the broader eligibility conversation with the prescriber.

Which other medications does the post connect to added hypoglycemia or dehydration risk?

The article names insulin, SGLT2 inhibitors, and certain blood pressure medications as agents that may interact with tirzepatide and raise the risk of hypoglycemia or dehydration. It says patients already on those drugs need baseline adjustment conversations with their prescriber and close glucose or blood pressure monitoring after starting. A full current-medication audit is part of its recommended screening.

Related Reading

• Can You Avoid Diabetes If It Runs In Your Family
• Lifemd Tirzepatide
• Goodlife Meds Tirzepatide
• Noom Tirzepatide

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.